SCHEMBL4033412

SCHEMBL4033412

Cc1c(Cl)ccc(S(N)(=O)=O)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 7/20 0.42
CA2 P00918 7/20 0.42
CA4 P22748 4/20 0.42
CA12 O43570 4/20 0.42
CA9 Q16790 4/20 0.42
CA6 P23280 3/20 0.42
CA5A P35218 3/20 0.42
CA7 P43166 3/20 0.42
CA14 Q9ULX7 3/20 0.42
CA5B Q9Y2D0 3/20 0.42
LMNA P02545 2/20 0.42
CYP2C9 P11712 2/20 0.42
CA13 Q8N1Q1 2/20 0.42
WDR5 P61964 1/20 0.42
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 1/20 0.41
CA3 P07451 2/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.38
APEX1 P27695 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7591942 0.85 ALDH1A1 (0.43) CA1CA2CA4CA12CA9
SCHEMBL3550070 0.81 LMNA (0.43) LMNAWDR5ALDH1A1POLBL3MBTL1
SCHEMBL2017068 0.81 LMNA (0.43) LMNAWDR5ALDH1A1L3MBTL1TSHR
SCHEMBL6038911 0.80 CA1 (0.48) CA1CA2CA4CA12CA9
SCHEMBL4184750 0.80 CA1 (0.37) CA1CA2CA4CA12CA9
SCHEMBL20486314 0.80 CYP2D6 (0.42) CA1CA2CA4CA12CA9
SCHEMBL10014825 0.79 WDR5 (0.46) LMNAWDR5CYP2D6CYP2C19ALDH1A1
SCHEMBL3091342 0.77 CA2 (0.45) CA1CA2CA4CA12CA9
SCHEMBL4030951 0.76 WDR5 (0.50) CA1CA2CA4CA12CA9
SCHEMBL13687112 0.76 CA2 (0.40) CA1CA2CA4CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521744-B1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS FOURNIER LAB SA (FR) 2009-04-01 EP disclosed
US-7361687-B2 Arylsulphonamide derivatives and methods of preparing LABORATOIRES FOURNIER SA (FR) 2008-04-22 US disclosed
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents LABORATOIRES FOURNIER SA (FR) 2006-04-20 US disclosed
EP-1521744-A1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS LABORATOIRES FOURNIER S.A. (FR) 2005-04-13 EP disclosed
WO-2003106428-A1 NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS LABORATOIRES FOURNIER SA (FR) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents UGT1A1, UGT2B7, UGT1A6 CA1 4872/4885CA2 4757/4885CA4 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.